Composition:

Deltarhino nasal spray contains:

Ephedrine hydrochloride 0.5 % w/v.

Naphazoline nitrate 0.125 % w/v.

Pharmacodynamics:

Deltarhino, nasal decongestant, consists of Ephedrine hydrochloride & Naphazoline nitrate.

Ephedrine is a sympathomimetic with direct & indirect effects on adrenergic receptors.

It has alpha-(a) & beta-(13) adrenergic activity & has pronounced stimulating effects on the central nervous system.

Naphazoline is a sympathomimetic with marked a -adrenergic activity.

It has rapid & prolonged action in reducing swelling & congestion when applied to mucous membranes.

The a -adrenergic effects cause intense vasoconstriction when applied directly to mucous membranes, redistributing local blood flow to reduce edema of the nasal mucosa thus resulting in its shrinkage, promoting drainage & improving ventilation & nasal stuffiness.

The presence of the combination of ephedrine hydrochloride & naphazoline nitrate produces a rapid & prolonged decongestion of the inflamed nasal mucosa at the usual therapeutic doses.

After a prolonged use of sympathomimetics, rebound congestion occurs as vasodilatation becomes prominent & the effects of vasoconstriction subside.

Therefore, its use is restricted to periods of not more than 7 consecutive days.

 Therapeutic Indications:

Symptomatic relief of nasal & nasopharyngeal mucosal congestion due to:

Common cold.

Sinusitis.

Rhinitis.

Hay fever.

Other upper respiratory allergies.

Adjunctive therapy of the middle ear infections as nasal spray by decreasing congestion around the Eustachian Ostia.

Dosage and Administration:

Adults & children > 12 years old:

One or two sprays to be sprayed in each nostril three times daily.

N.B: do not share container with other patients. Do not allow tip of the container to touch the nasal passage. Discard after medication is no longer required.

Keep head upright. Sniff hard for a few minutes after use.

Precautions:

Acute use: use topical decongestants only in acute states & no longer than 7 days.

Care in patients with hypertension or other cardiovascular diseases, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, renal impairment or angle-closure glaucoma.

Notify physician of insomnia, dizziness, weakness, tremor, irregular heartbeat.

With patients taking monoamine-oxidase inhibitors (MAOIs).

Deltarhino, is not recommended for children less than 12 years of age.

Contraindications:

Known hypersensitivity reactions to any of the components of the product.

Risk of urinary retention linked with urinary prostatic disorders.

Pregnancy & lactation.

Adverse Reactions:

Burning; stinging; sneezing; dryness; local irritation; rebound congestion.

Systemic effects, including nausea, headache, & dizziness have occurred after local administration of naphazoline.

Presentation & Storage:

Deltarhino nasal spray is supplied in plastic bottles of 15 ml each.

Store at a room temperature.